[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602036":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Sheba Medical Center","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients",null,"Patients with OPMD",{"label":13,"type":10,"description":14,"interventionNames":10},"Control","Unaffected spouse or household member without OPMD",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Naama Study coordinator","CONTACT","+972 55 2929006","opmd@sheba.health.gov.il",[22],{"facility":5,"status":23,"city":24,"state":10,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Ramat Gan","Israel","IL",{"type":28,"coordinates":29},"Point",[30,31],34.81065,32.08227,{"lat":31,"lon":30},[34,37,40],{"name":17,"role":18,"phone":35,"phoneExt":10,"email":36},"+972552929006","OPMD@sheba.health.gov.il",{"name":38,"role":39,"phone":10,"phoneExt":10,"email":10},"Alex Zvulunov, MD, MHA","PRINCIPAL_INVESTIGATOR",{"name":41,"role":42,"phone":10,"phoneExt":10,"email":10},"Silvina Friedlander-Barenboim, DMD","SUB_INVESTIGATOR",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602036","oral-health-saliva-viscosity-and-composition-in-oculo-pharyngeal-muscular-dystrophy-opmd-100602036",false,"NCT07118280","Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)","Saliva Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)","Inclusion Criteria:\n\n* Patients with OPMD and their spouses or household members\n\nExclusion Criteria:\n\n* • Pregnancy or presence of any disease that may affect a composition of saliva","ALL","18 Years",{"count":55,"type":56},100,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to explore whether oral health and saliva viscosity and composition in Oculopharyngeal Muscular Dystrophy (OPMD) is different from control subjects.\n\nThe main questions it aims to answer are:\n\nDo swallowing disturbances in OPMD adversely affect oral health? Is saliva thickness (viscosity) is increased in OPMD? Does saliva in OPMD contains biochemical markers of the disease?",[61],"Oculopharyngeal Muscular Dystrophy","2026-01-25",{"date":64,"type":65},"2026-01-27","ACTUAL",{"date":67,"type":65},"2023-03-01",{"date":69,"type":56},"2027-03",{"name":5,"class":6},1]